Sheila Jacobs

All articles by Sheila Jacobs

• Avapritinib shows positive results as SM treatment in phase 2 trial

  Findings from the phase 2 PATHFINDER study presented at SOHO 2024 showed avapritinib had an overall positive effect in SM patients.

• FDA approves first nasal spray for type 1 allergic reactions

  ARS Pharmaceuticals recently announced its nasal spray for type 1 allergic reactions has received FDA approval.

• Case study: 4-year old diagnosed with both AML and SM

  A recently published case study described a 4-year-old girl with both amyloid myeloid leukemia (AML) and systemic mastocytosis (SM).

• Study explores potential role of eosinophils in non-advanced SM

  A recent study found targeting eosinophils in nonadvanced SM may help those who have not found success with other treatments.

• Report finds severe and atypical symptoms associated with SM

  A recent study showed SM can be associated with severe complications and atypical symptoms, highlighting the need for a uniform diagnostic approach.

• Chest CT scans can find bronchial, lung lesions in SM patients

  According to a recent study, chest CT scans are able to identify bronchial or lung lesions in patients with systemic mastocytosis (SM).

• FDA approves generic equivalent to Novartis’ Rydapt to treat SM

  Lupin Limited recently announced it has received approval from the FDA for its midostaurin 25 mg capsules to treat aggressive SM.

• Key genetic association found between KIT M541L variant and SM

  A recent study found a genetic association between the KIT M541L variant and mastocytosis—SM and CM, in particular.

• Long COVID may be linked to mast cell activation syndrome

  Long COVID, which is also called long-term COVID or post-COVID syndrome, may be linked to mast cell activation syndrome (MCAS).

• Increased awareness of SM linked to improved patient care

  A recent report shows increased awareness of systemic mastocytosis (SM) is associated with fewer diagnostic delays, which leads to better patient care.